UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000010783 |
|---|---|
| Receipt number | R000012615 |
| Scientific Title | Exploratory Clinical Trial of EPI-743 in Japanese MELAS Syndrome Patients |
| Date of disclosure of the study information | 2013/05/23 |
| Last modified on | 2013/05/22 17:51:23 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Exploratory Clinical Trial of EPI-743 in
Japanese MELAS Syndrome Patients
Acronym
EPI-743 Therapy for Japanese MELAS
Scientific Title
Exploratory Clinical Trial of EPI-743 in
Japanese MELAS Syndrome Patients
Scientific Title:Acronym
EPI-743 Therapy for Japanese MELAS
Region
| Japan |
Condition
Condition
MELAS: mitochondrial
myopathy, encephalopathy, lactic acidosis and stroke-like episodes
Classification by specialty
| Medicine in general | Cardiology | Pneumology |
| Endocrinology and Metabolism | Hematology and clinical oncology | Neurology |
| Pediatrics | Radiology |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
1) Pharmacokinetics of EPI-743 in affected Japanese juvenile and adult patients
2) Efficacy and safety evaluation
Basic objectives2
Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Tabulate EPI-743 blood concentrations and calculate fundamental pharmacokinetic parameters
Key secondary outcomes
1) Lactate levels at MRS testing
2) blood and CSF concentrations of lactate and pyruvate
3) QOL values (SF-36, PedsQL)
4) Mitochondrial disease evaluation scale scores (NPMDS or NMDAS)
5) Incidence of abnormal brain waves
6) Incidence of epileptiform seisures
7) Fatigue level
8) Safety evaluation
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Single-dose as Step 1 (Table 1), repeated-dose as Step 2 (Table 2). In Step 1, the drug is administered orally during breakfast, and after confirming no safety problems during 7 days of observation, the trial proceeds to Step 2. In Step 2, the drug is administered orally three times daily, once each during breakfast, lunch, and dinner, for a period of 12 weeks.
Table 1 Step 1: Single-Dose
Children (aged 6-15): Dosage 100mg; No. of Doses, Once; No. of Cases, 5; Observation after dosing, 7 days
Adults (aged 16-59): Dosage 100mg; No. of Doses, Once; No. of Cases, 5; Observation after dosing, 7 days
Table 2 Step2: Repeated-Dose
Children (aged 6-15): Dosage 15mg/kg up to 200 mg; No. of Dosing days, 3 times per day for 12 weeks; No. of Cases, 5; Final Observation, 1 day after last dose
Adults (aged 16-59): Dosage 300mg each time; No. of Dosing days, 3 times per day for 12 weeks; No. of Cases, 5; Final Observation, 1 day after last dose
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 6 | years-old | <= |
Age-upper limit
| 60 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1) Patients diagnosed with MELAS syndrome
2) Patients aged 6 to 59 at the time of consent
3) After adequate explanation regarding trial participation, patients who have
adequately understood the explanation and have freely provided written
agreement (or assent) and for whom a legal representative's written
consent has been obtained
4) Patients that have a care provider who can ensure that the trial protocol is
followed
5) Patients for whom the use of general pharmaceuticals can be prohibited
6) Patients for whom the ingestion of foods or beverages fortified with
coenzyme Q10 or vitamin E can be prohibited for over 8 weeks prior to the
administration start and for the duration of the trial.
7) Patients for whom the use of ubidecarenone, idebenone, and dichloroacetate can be prohibited for over 8 weeks prior to the
administration start and for the duration of the trial.
Key exclusion criteria
1) Patients for whom the MELAS syndrome genetic mutation has not been
confirmed
2) Patients who cannot undergo magnetic resonance spectroscopy (MRS)
3) Patients allergic to EPI-743 or to sesame oil
4) Patients with a bleeding tendency, or with abnormal PT/PTT values (INR
1.5 or higher)
5) Patients with AST or ALT values of more than double the institutional limit
6) Patients with renal failure and who require dialysis
7) Patients with fat malabsorption syndrome that impedes drug absorption
8) Patients with pyruvate dehydrogenase (PDH) deficiency or other inborn
error of metabolism
9) Patients who are pregnant or planning to become pregnant
10) Patients with an alcohol dependency or who are illegal drug users
11) Patients with severe heart failure accompanied by lactate acidosis
12) Patients who have received another trial drug or test drug within three
months of the start of dosing of the test drug in this trial
13) Patients with a history of severe drug hypersensitivity
14) Other patients deemed by the researchers to be unsuitable for this trial
Target sample size
10
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yuichi Goto |
Organization
National Center Hospital, National Center of Neurology and Psychiatry
Division name
Pediatric Neurology
Zip code
Address
4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8551, Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Akemi Tamaura |
Organization
National Center Hospital, National Center of Neurology and Psychiatry
Division name
Clinical Research Unit
Zip code
Address
4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8551, Japan
TEL
042-346-2711
Homepage URL
tamaura@ncnp.go.jp
Sponsor or person
Institute
National Center of Neurology and Psychiatry, Japan
Institute
Department
Personal name
Funding Source
Organization
Edison Pharmaceuticals, Inc
Organization
Division
Category of Funding Organization
Outside Japan
Nationality of Funding Organization
USA
Other related organizations
Co-sponsor
Edison Pharmaceuticals, Inc
Name of secondary funder(s)
Ministry of Health, Labour and Welfare, Japan
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
独立行政法人 国立精神・神経医療研究センター（東京都）
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 05 | Month | 23 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2013 | Year | 05 | Month | 23 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 05 | Month | 23 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 05 | Month | 22 | Day |
Last modified on
| 2013 | Year | 05 | Month | 22 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012615
